Lm::Mtb9Ag
This TB vaccine candidate comprises a live attenuated Listeria monocytogenes vector with two major virulence gene deletions and a T-cell immunity enhancing mutation (Lm ΔactA ΔinlB prfA*) that expresses nine M. tuberculosis immunoprotective proteins (Mpt64, TB10.4, ESAT-6, CFP10, Ag85B, EsxN, PPE68, EspA, and TB8.4 – four absent from BCG) from two chromosomal fusion protein expression…
Read MoreBCG w/MK-2206
Parental BCG efficacy is mainly hampered by its low induction of apoptosis along with high secretion of the immunosuppressive cytokine IL-10. We found that the host transcription factor FOXO3 mediates both, BCG-induced apoptosis and inhibition of IL-10 secretion. The novel vaccination procedure consists of induction of FOXO3 activity, during BCG vaccination, using an anti-cancer drug,…
Read MoreSpray Dried ID93+GLA-SE
AAHI’s tuberculosis vaccine candidate includes a recombinant fusion subunit protein antigen, ID93, formulated with GLA-SE, a squalene emulsion containing the synthetic Toll-like receptor 4 agonist glucopyranosyl lipid A (GLA). The vaccine candidate was developed on AAHI’s formulation (adjuvant and delivery vehicle) vaccine platform.
Read More